| scholarly article | Q13442814 |
| P50 | author | Joseph Jankovic | Q6284337 |
| P2093 | author name string | Weidong Le | |
| Pavani Sayana | |||
| P2860 | cites work | Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice | Q21142674 |
| DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation | Q21146396 | ||
| Parkinson's Disease: Genetics and Pathogenesis | Q22242000 | ||
| Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis | Q22242250 | ||
| A call for transparent reporting to optimize the predictive value of preclinical research | Q24289327 | ||
| Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1 | Q24290518 | ||
| Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition | Q24300958 | ||
| Kinase activity of mutant LRRK2 mediates neuronal toxicity | Q24303603 | ||
| Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis | Q24304952 | ||
| Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism | Q24309753 | ||
| Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity | Q24338647 | ||
| The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease | Q24338845 | ||
| A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD) | Q24612655 | ||
| Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. | Q24647634 | ||
| Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism | Q24797276 | ||
| Genetics of Parkinson's disease | Q26827825 | ||
| Should clinicians care about preclinical animal research? | Q86425884 | ||
| Therapies in Parkinsonʼs disease | Q38018193 | ||
| Emerging therapies for Parkinson's disease | Q38024685 | ||
| Lysosome-dependent pathways as a unifying theme in Parkinson's disease. | Q38038561 | ||
| F-Box Only Protein 7 Gene in Parkinsonian-Pyramidal Disease | Q38074018 | ||
| What’s to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease? | Q38077612 | ||
| The VPS35 gene and Parkinson's disease | Q38093808 | ||
| Lithium protects against oxidative stress‐mediated cell death in α‐synuclein‐overexpressing in vitro and in vivo models of Parkinson's disease | Q38333893 | ||
| Therapeutic effect of near infrared NIR light on Parkinson’s disease models | Q38472098 | ||
| Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease | Q39282544 | ||
| Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. | Q39361088 | ||
| A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease | Q39414467 | ||
| Phenylbutyrate Up-regulates the DJ-1 Protein and Protects Neurons in Cell Culture and in Animal Models of Parkinson Disease | Q39582058 | ||
| Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin. | Q39681468 | ||
| Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains | Q39782948 | ||
| MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism | Q39906818 | ||
| Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine | Q40014225 | ||
| Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. | Q40053132 | ||
| Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae | Q41173089 | ||
| Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease | Q41472825 | ||
| Spread of neuronal degeneration in a dopaminergic,Lrrk-G2019Smodel of Parkinson disease | Q41510711 | ||
| Effect of Quercetin in the 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-Induced Mouse Model of Parkinson's Disease | Q42227324 | ||
| An effective novel delivery strategy of rasagiline for Parkinson's disease | Q42728502 | ||
| Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia | Q42777922 | ||
| Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice | Q42959416 | ||
| Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease | Q42962537 | ||
| Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease | Q43053817 | ||
| Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease | Q43065956 | ||
| Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease | Q43090325 | ||
| Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons | Q43218195 | ||
| Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. | Q43235352 | ||
| Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. | Q43260033 | ||
| The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease | Q43273235 | ||
| Carrier-mediated processes in blood--brain barrier penetration and neural uptake of paraquat | Q43656845 | ||
| The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein | Q43798526 | ||
| Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson’s Disease | Q27301885 | ||
| Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease | Q27335848 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure | Q28145614 | ||
| Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat | Q28215248 | ||
| LRRK2 in Parkinson's disease: protein domains and functional insights | Q28235024 | ||
| Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions | Q28245021 | ||
| Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo | Q28255552 | ||
| Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial | Q28296434 | ||
| Idebenone and resveratrol extend lifespan and improve motor function of HtrA2 knockout mice | Q28478469 | ||
| Parkin-deficient mice are not a robust model of parkinsonism | Q28504677 | ||
| Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1 | Q28506681 | ||
| Development and Characterization of a New Parkinson's Disease Model Resulting from Impaired Autophagy | Q28511536 | ||
| Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cells | Q28587554 | ||
| Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons | Q28590748 | ||
| Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. | Q28593258 | ||
| Loss of locus coeruleus neurons and reduced startle in parkin null mice | Q28593443 | ||
| Mitochondrial dysfunction and oxidative damage in parkin-deficient mice | Q28593859 | ||
| Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease | Q28740551 | ||
| Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders | Q29614754 | ||
| Chronic systemic pesticide exposure reproduces features of Parkinson's disease | Q29614763 | ||
| Association between early-onset Parkinson's disease and mutations in the parkin gene | Q29615733 | ||
| The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. | Q30458705 | ||
| LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors | Q30524899 | ||
| Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse | Q30541996 | ||
| Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists | Q33228401 | ||
| Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine | Q33344779 | ||
| Tests to assess motor phenotype in mice: a user's guide | Q33464903 | ||
| Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease | Q33522039 | ||
| Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. | Q33594388 | ||
| Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity | Q33617472 | ||
| Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease | Q33754793 | ||
| Behavioral phenotyping of mouse models of Parkinson's disease | Q33820609 | ||
| Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease | Q33835301 | ||
| Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders | Q33835599 | ||
| Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients | Q37027502 | ||
| The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease | Q37054679 | ||
| Bladder and bowel dysfunction in Parkinson's disease | Q37104716 | ||
| Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model | Q37289669 | ||
| Etiopathogenesis of Parkinson disease: a new beginning? | Q37325334 | ||
| Paraquat and Parkinson's disease | Q37679695 | ||
| Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity | Q37683630 | ||
| Dopamine receptor agonists and depression in Parkinson's disease | Q37685695 | ||
| Genetic animal models of Parkinson's disease | Q37765030 | ||
| Parkinson's disease: the non-motor issues | Q37899473 | ||
| Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline | Q37939755 | ||
| Spotlight on Rotigotine Transdermal Patch in Parkinsonʼs Disease† | Q37960901 | ||
| Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. | Q44251931 | ||
| Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats | Q44334197 | ||
| Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype | Q44545273 | ||
| The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA. | Q44844737 | ||
| Effects of high frequency deep brain stimulation on urine storage and voiding function in conscious minipigs | Q44851830 | ||
| Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys | Q45390357 | ||
| DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice | Q45865989 | ||
| The effects of pergolide on memory and oxidative stress in a rat model of Parkinson's disease. | Q45903649 | ||
| Effects of Plantago ovata husk on levodopa (with Carbidopa) bioavailability in rabbits with autonomic gastrointestinal disorders. | Q46038792 | ||
| Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease | Q46046500 | ||
| A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. | Q46061994 | ||
| Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson's disease | Q46074697 | ||
| Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models | Q46358011 | ||
| Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration | Q46654865 | ||
| Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets | Q46717685 | ||
| The effects of short-term nicotine administration on behavioral and oxidative stress deficiencies induced in a rat model of Parkinson's disease | Q47611823 | ||
| Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions | Q48027710 | ||
| Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway | Q48108789 | ||
| The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. | Q48144769 | ||
| Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. | Q48170542 | ||
| Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys | Q48197305 | ||
| Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss | Q48253717 | ||
| 100 years of Lewy pathology | Q48278741 | ||
| Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys | Q48325968 | ||
| Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice | Q48335901 | ||
| Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets | Q48347120 | ||
| Identification of a series of highly potent activators of the Nurr1 signaling pathway | Q48398582 | ||
| Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system | Q48403198 | ||
| Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model | Q48498265 | ||
| Anti-Parkinsonian Effects of Nurr1 Activator in Ubiquitin-Proteasome System Impairment Induced Animal Model of Parkinson’s Disease | Q48580281 | ||
| Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein | Q48581887 | ||
| Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats. | Q48597422 | ||
| Motor disorders and impaired electrical power of pallidal EEG improved by gallic acid in animal model of Parkinson's disease | Q48659917 | ||
| Protective effects of baicalein against rotenone-induced neurotoxicity in PC12 cells and isolated rat brain mitochondria | Q48842987 | ||
| Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats | Q48939742 | ||
| Paraquat induces behavioral changes and cortical and striatal mitochondrial dysfunction | Q48983439 | ||
| Alpha‐synuclein in colonic submucosa in early untreated Parkinson's disease | Q49037483 | ||
| 6-hydroxy-dopamine induced degeneration of central monoamine neurons | Q49122002 | ||
| Assessment of the treatment effect of baicalein on a model of Parkinsonian tremor and elucidation of the mechanism | Q50259411 | ||
| DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease | Q51051455 | ||
| Paraquat-induced oxidative stress in drosophila melanogaster: effects of melatonin, glutathione, serotonin, minocycline, lipoic acid and ascorbic acid | Q52673945 | ||
| Protective Effect of Lycopene on Oxidative Stress and Cognitive Decline in Rotenone Induced Model of Parkinson’s Disease | Q52718634 | ||
| Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease. | Q52721046 | ||
| Melatonin protects against rotenone‐induced cell injury via inhibition of Omi and Bax‐mediated autophagy in Hela cells | Q52726872 | ||
| DJ-1 and Parkin Modulate Dopamine-dependent Behavior and Inhibit MPTP-induced Nigral Dopamine Neuron Loss in Mice | Q54105201 | ||
| A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients | Q60050820 | ||
| Disulfiram and Diethyldithiocarbamate Intoxication Affects the Storage and Release of Striatal Dopamine | Q63431061 | ||
| Animal models of Parkinson's disease | Q83260343 | ||
| AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials | Q83836532 | ||
| Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats | Q84747847 | ||
| Pathogenesis of Parkinson's disease | Q84882756 | ||
| The role of transcription factor Pitx3 in dopamine neuron development and Parkinson's disease | Q33861795 | ||
| Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. | Q33941736 | ||
| Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models | Q33964804 | ||
| A neuroprotective role for angiogenin in models of Parkinson’s disease | Q34024770 | ||
| The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. | Q34148223 | ||
| Mutations in NR4A2 associated with familial Parkinson disease | Q34166532 | ||
| Role of LRRK2 kinase dysfunction in Parkinson disease | Q34192817 | ||
| Sleep alterations in an environmental neurotoxin-induced model of parkinsonism | Q34203614 | ||
| Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation | Q34223052 | ||
| α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons | Q34503671 | ||
| REM Sleep Behavior Disorder in the Marmoset MPTP Model of Early Parkinson Disease | Q35110581 | ||
| Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons | Q35167964 | ||
| Bladder, bowel, and sexual dysfunction in Parkinson's disease | Q35209869 | ||
| Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons | Q35611727 | ||
| Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. | Q35651220 | ||
| Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model | Q35654251 | ||
| SIRT1 Protects against α-Synuclein Aggregation by Activating Molecular Chaperones | Q35686386 | ||
| Modeling Parkinson's disease in primates: The MPTP model | Q35765748 | ||
| Adenosine A2A receptor gene disruption protects in an α‐synuclein model of Parkinson's disease | Q35799088 | ||
| The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease | Q35894167 | ||
| Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice | Q35946149 | ||
| Alterations in axonal transport motor proteins in sporadic and experimental Parkinson’s disease | Q36063269 | ||
| Late-onset Parkinsonism in NFκB/c-Rel-deficient mice | Q36218699 | ||
| Animal models of the non-motor features of Parkinson's disease | Q36235578 | ||
| A mechanism of paraquat toxicity involving nitric oxide synthase | Q36555889 | ||
| Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease involves cross talk between inflammatory and Wnt/β-catenin signaling pathways: functional consequences for n | Q36566007 | ||
| Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α‐synuclein | Q36585297 | ||
| Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery | Q36610346 | ||
| Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease | Q36656691 | ||
| α-Synuclein oligomers and clinical implications for Parkinson disease | Q36718306 | ||
| Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease | Q36750148 | ||
| In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? | Q36976137 | ||
| Resveratrol-Activated AMPK/SIRT1/Autophagy in Cellular Models of Parkinson’s Disease | Q36977322 | ||
| Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease | Q37016310 | ||
| P433 | issue | 1 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 92-110 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Neurotherapeutics | Q15716631 |
| P1476 | title | Animal models of Parkinson's disease: a gateway to therapeutics? | |
| P478 | volume | 11 |
| Q24282619 | Association between Parkinson's Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis |
| Q47828355 | Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson's Disease. |
| Q58338615 | Changes in Motor Activity and the Sleep–Waking Cycle in an MPTP Model of Parkinson’s Disease in Mice |
| Q64864808 | Degree of dopaminergic degeneration measured by 99mTc-TRODAT-1 SPECT/CT imaging |
| Q52650242 | Early Life Stress, Depression And Parkinson's Disease: A New Approach |
| Q42736439 | Editorial: Neurotherapeutics of movement disorders |
| Q53386963 | G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system |
| Q36554791 | Ion mobility mass spectrometry enhances low-abundance species detection in untargeted lipidomics |
| Q28602694 | L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history |
| Q40458313 | Media hype: Patient and scientific perspectives on misleading medical news. |
| Q26772285 | Modeling Parkinson's disease in the common marmoset (Callithrix jacchus): overview of models, methods, and animal care |
| Q47919698 | N-Acetyl-l-Cysteine Protects Astrocytes against Proteotoxicity without Recourse to Glutathione |
| Q87617102 | N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF |
| Q52771856 | Oral supplements of aqueous extract of tomato seeds alleviate motor abnormality, oxidative impairments and neurotoxicity induced by rotenone in mice: relevance to Parkinson's disease. |
| Q27312184 | Oxidative Stress Triggers Body-Wide Skipping of Multiple Exons of the Spinal Muscular Atrophy Gene |
| Q33818612 | Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS |
| Q90592820 | Protective effect of roscovitine against rotenone-induced parkinsonism |
| Q36176121 | Proteomic Analysis of the Effect of Korean Red Ginseng in the Striatum of a Parkinson's Disease Mouse Model |
| Q92860326 | Rotenone-induced inner retinal degeneration via presynaptic activation of voltage-dependent sodium and L-type calcium channels in rats |
| Q46411575 | Sodium Selenite Prevents Paraquat-Induced Neurotoxicity in Zebrafish. |
| Q60950155 | The Search for Environmental Causes of Parkinson's Disease: Moving Forward |
| Q35898196 | The temporary and accumulated effects of transcranial direct current stimulation for the treatment of advanced Parkinson's disease monkeys |
| Q33807060 | Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression |
| Q26991826 | Therapy for Parkinson's disease: what is in the pipeline? |
| Q37004246 | Up-regulation of SNCA gene expression: implications to synucleinopathies |
| Q26782120 | When rejuvenation is a problem: challenges of modeling late-onset neurodegenerative disease |
| Q46579323 | iPS cells in the study of PD molecular pathogenesis |
Search more.